{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:32:36Z","timestamp":1787239956631,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013061","name":"Jilin Scientific and Technological Development Program","doi-asserted-by":"publisher","award":["YDZJ202201ZYTS559"],"award-info":[{"award-number":["YDZJ202201ZYTS559"]}],"id":[{"id":"10.13039\/501100013061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81260226"],"award-info":[{"award-number":["81260226"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bioorg.2026.109521","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:12:32Z","timestamp":1768867952000},"page":"109521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design, synthesis and biological evaluation of novel isoalantolactone-benzylamine derivatives leading to the discovery of a PARP1 inhibitor with selective cytotoxicity against MCF-7 breast cancer cells"],"prefix":"10.1016","volume":"170","author":[{"given":"Bo","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deao","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangchun","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109521_bb0005","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109521_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116535","article-title":"Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship","volume":"274","author":"Das","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109521_bb0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40265-019-01235-5","article-title":"Poly (ADP-ribose) polymerase inhibition in patients with breast cancer and BRCA 1 and 2 mutations","volume":"80","author":"Jerez","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109521_bb0020","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2174\/1574892813666180305165256","article-title":"PARP inhibitors in ovarian cancer","volume":"13","author":"Mittica","year":"2018","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.bioorg.2026.109521_bb0025","first-page":"658","article-title":"PARP inhibitors for breast cancer treatment: A review","volume":"10","author":"Morganti","year":"2024","journal-title":"J. Am. Med. Assoc. Oncol."},{"key":"10.1016\/j.bioorg.2026.109521_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150943","article-title":"Poly (ADP-ribose) polymerase1 (PARP1) and PARP inhibitors: new frontiers in cervical cancer","volume":"738","author":"Rajawat","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2026.109521_bb0035","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109521_bb0040","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/0018578717719183","article-title":"Drug monographs: Olaratumab and Rucaparib","volume":"52","author":"Waddell","year":"2017","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.bioorg.2026.109521_bb0045","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.2174\/0109298673263854231009063053","article-title":"Synthesis and selective anticancer activity evaluation of 2-phenylacrylonitrile derivatives as tubulin inhibitors","volume":"31","author":"Jin","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109521_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113054","article-title":"Targeting cancer signaling pathways by natural products: exploring promising anti-cancer agents","volume":"150","author":"Hashem","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.109521_bb0055","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1021\/acs.jmedchem.6b00400","article-title":"Isatin derived spirocyclic analogues with \u03b1-Methylene-\u03b3-butyrolactone as anticancer agents: A structure\u2013activity relationship study","volume":"59","author":"Rana","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109521_bb0060","first-page":"1","article-title":"Isoalantolactone induces cell cycle arrest, apoptosis and autophagy in colorectal cancer cells","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109521_bb0065","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/jpp\/rgac103","article-title":"Research progress on pharmacological effects of isoalantolactone","volume":"75","author":"Xu","year":"2023","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109521_bb0070","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1002\/adsc.202300316","article-title":"Weak nucleophiles in the Aza-Michael reaction","volume":"365","author":"Rulev","year":"2023","journal-title":"Adv. Synth. Catal."},{"key":"10.1016\/j.bioorg.2026.109521_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108124","article-title":"Synthesis and exploration of anticancer potential of spirocyclic 1,2,3-triazoline and aziridine derivatives of natural eudesmanolide isoalantolactone","volume":"155","author":"Patrushev","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109521_bb0080","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1007\/s10593-021-03030-1","article-title":"Synthetic transformations of sesquiterpene lactones. Controllable synthesis of 11,13-dihydroisoalantolactone azides and 13-(1,2,3-triazolyl) eudesmanolides based on sesquiterpene lactones","volume":"57","author":"Patrushev","year":"2022","journal-title":"Chem. Heterocycl. Compd."},{"key":"10.1016\/j.bioorg.2026.109521_bb0085","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/molecules28041717","article-title":"Development of combretastatin A-4 analogues as potential anticancer agents with improved aqueous solubility","volume":"28","author":"Chen","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.109521_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2025.111528","article-title":"Targeting breast cancer cells with 2-indolyl-1,3,4-oxadiazole compounds by inducing apoptosis, paraptosis and autophagy","volume":"415","author":"Uppar","year":"2025","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2026.109521_bb0095","first-page":"814","article-title":"Recent advances on the structural modification of parthenolide and its derivatives as anticancer agents","volume":"20","author":"Liu","year":"2022","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.bioorg.2026.109521_bb0100","first-page":"3550","article-title":"Synthesis and evaluation in vitro of dihydrothiophenopyridine chalcone derivatives as anticancer activity agents","volume":"09","author":"Liu","year":"2021","journal-title":"Org. Chem."},{"key":"10.1016\/j.bioorg.2026.109521_bb0105","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s10549-011-1441-2","article-title":"PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy","volume":"127","author":"Domagala","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bioorg.2026.109521_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114116","article-title":"Design, synthesis and mechanism studies of novel dual PARP1\/BRD4 inhibitors against pancreatic cancer","volume":"230","author":"Huang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109521_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010157","article-title":"Degradation of PARP1 by MARCHF3 in tumor cells triggers cCAS-STING activation in dendritic cells to regulate antitumor immunity in hepatocellular carcinoma","volume":"12","author":"Cao","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bioorg.2026.109521_bb0120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13046-025-03441-4","article-title":"PARP-1 as a novel target in endocrine-resistant breast cancer","volume":"44","author":"Zicarelli","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109521_bb0125","article-title":"Circular RNA circATM binds PARP1 to suppress Wnt\/\u03b2-catenin signaling and induce cell cycle arrest in gastric cancer cells","volume":"25","author":"Zhu","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.bioorg.2026.109521_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.identj.2025.106077","article-title":"Sacc Ev-Col1 homotrimer promote tregs infiltration via fibroblast activation","volume":"75","author":"Dong","year":"2025","journal-title":"Int. Dent. J."},{"key":"10.1016\/j.bioorg.2026.109521_bb0135","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/09553002.2019.1605461","article-title":"Autophagy suppresses radiation damage by activating PARP-1 and attenuating reactive oxygen species in hepatoma cells","volume":"95","author":"Wang","year":"2019","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.bioorg.2026.109521_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117703","article-title":"Hit to lead optimization of isopentenyl chalcones as novel MTHFD2 inhibitors for cancer treatment: design, synthesis, in-vitro, in-vivo and in-silico studies","volume":"292","author":"Hu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109521_bb0145","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.freeradbiomed.2024.12.052","article-title":"PARP1 inhibitor niraparib exerts synergistic antimyeloma effect with bortezomib through inducing DNA damage and inhibiting DNA repair","volume":"228","author":"Zhang","year":"2025","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bioorg.2026.109521_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117332","article-title":"Structural optimization and characterization of highly potent and selective STAT3 inhibitors for the treatment of triple negative breast cancer","volume":"287","author":"Jin","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109521_bb0155","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1021\/acs.bioconjchem.5c00459","article-title":"Mitochondria-targeting antimicrobial peptide (AMP) regulating N6-methyladenosine (m6A) modification to promote colon cancer ferroptosis","volume":"36","author":"Li","year":"2025","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bioorg.2026.109521_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2025.117489","article-title":"Ceritinib (LDK378) inhibits laryngeal squamous cell carcinoma progression via regulating ROS-induced mitochondrial apoptosis and inducing oxidative stress","volume":"503","author":"Wang","year":"2025","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109521_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115924","article-title":"Mangiferin targeting HSP90\u03b1 induces DNA damage in cutaneous squamous cell carcinoma via the ROS\/MAPK signaling pathway","volume":"168","author":"Jie","year":"2026","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2026.109521_bb0170","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.tranon.2015.04.004","article-title":"Expression of DNA damage response molecules PARP1, \u03b3H2AX, BRCA1, and BRCA2 predicts poor survival of breast carcinoma patients","volume":"8","author":"Park","year":"2015","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bioorg.2026.109521_bb0175","first-page":"20210","article-title":"DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition","volume":"10","author":"Viera","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109521_bb0180","doi-asserted-by":"crossref","first-page":"16917","DOI":"10.1021\/acs.jmedchem.3c01639","article-title":"Discovery of a highly potent and selective MYOF inhibitor with improved water solubility for the treatment of gastric cancer","volume":"66","author":"Gu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109521_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117442","article-title":"Discovery of novel small molecules targeting TGF-\u03b2 signaling for the treatment of non-small cell lung cancer","volume":"289","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109521_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.143667","article-title":"Synthesis and biological evaluation of novel benzohydrazide derivatives of substituted quinazoline-2,4(1H,3H)-diones as selective PARP-1 inhibitors with promising anti-proliferative activity","volume":"1349","author":"Tawfik","year":"2026","journal-title":"J. Mol. Struct."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600057X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600057X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:17:22Z","timestamp":1770067042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682600057X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":38,"alternative-id":["S004520682600057X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109521","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of novel isoalantolactone-benzylamine derivatives leading to the discovery of a PARP1 inhibitor with selective cytotoxicity against MCF-7 breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109521"}}